Effects of Blueberry on Cognition and Mobility in Older Adults

May 26, 2015 updated by: Barbara Shukitt-Hale, USDA Human Nutrition Research Center on Aging

Effects of Dietary Blueberry Supplementation on Cognition and Mobility in Healthy Older Adults

This study is being conducted to assess the effect of dietary blueberry supplementation on cognition and mobility in older adults. It is hypothesized that plant compounds, present in blueberries, may improve cognition and mobility by protecting against oxidative stress and inflammation.

Study Overview

Detailed Description

This study is being conducted to assess the effect of dietary blueberry supplementation vs. placebo on measures of cognition and mobility in older adults. Participants will visit the HNRCA on 4 occasions. During the first visit, participants will complete a dietary assessment and familiarize themselves with some of the cognitive tests used in the study. After a period of up to 45 days participants will return for the second visit. Participants will be randomized to consume either freeze dried blueberry powder or a placebo powder that tastes like blueberry. At visits 2, 3 and 4, participants will undergo tests of cognition, memory, gait and balance. In addition, blood samples and 24-hour urine will be collected at these visits. Tests include balance and gait assessment using a treadmill instrumented with pressure sensors which will measure postural sway and a variety of spatial/temporal gait parameters. Participants will also be affixed with surface electrodes to measure the activation of muscles in their legs during these balance and gait measurements. Participants will complete a battery of cognitive tests on paper and by computer. In the time between participants' visit 2 and visit 4, participants will receive a weekly telephone call to check in with them and remind them to continue taking the study powder. At the very end of the study, when all participants are finished, participants will receive a telephone call to debrief them and notify them which group they were randomized into. An optional tissue banking protocol will be offered for collection of additional blood to be banked at visits 2-4.

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02111
        • Jean Meyer USDA Human Nutrition Research Center on Aging at Tufts University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women are between the ages of 60 and 75 years
  • Body mass index 18.5-29.9 kg/m2
  • Adequate visual acuity or corrected visual acuity to read and perform computer tasks.
  • Fluency in spoken and written English
  • Ability to walk independently for 20 minutes
  • Absence of menstruation for a minimum of 12 months or surgical menopause.

Exclusion Criteria:

  • Self-reported vegetarian or vegan.
  • Any condition that has resulted in cognitive deficits, including but not limited to Alzheimer's disease or other dementias, cerebrovascular accident, or head injury
  • History of any neurologic disorder resulting in permanent or relapsing/remitting neurologic impairment including but not limited to Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, peripheral neuropathy, or radiculopathy.
  • History of any condition resulting in permanent muscle or mobility deficit that would interfere with walking independent of assistance for 20 minutes, including but not limited to amputation, fracture, arthritis, myopathy, or limb, hip or back surgery within the last year.
  • Self-reported cognitive, memory, neurologic or functional deficits that are stated to interfere with activities of daily living or functional status.
  • Any chronic condition associated with increased risk of falls such as vestibular disease, orthostatic hypotension or neuropathy.
  • Falls within the last year, that occurred in the course or routine daily activities, which were not precipitated by unusual circumstances such as being pushed or falling on ice.
  • Regular use (i.e. that cannot or should not be discontinued for the entire study period, as per the subject's personal physician) of medications or dietary supplements known or suspected to influence cognitive function, attention, ability to ambulate, gait, balance, or risk of falls that in the opinion of the study physician may influence study results or increase risk with participation in the study.
  • Psychiatric disorders that could in the opinion of the study physician interfere with study testing, including bipolar disorder, psychosis, and major depression
  • MMSE score of less than 24 at screening
  • Gastrointestinal disorders that influence digestion and absorption of food
  • Diabetes mellitus
  • Liver dysfunction
  • History of cirrhosis
  • SGPT, SGOT, or total bilirubin > 2 x upper limit of normal
  • Kidney disease as indicated by serum creatinine > 1.5 mg/dL at screening
  • Cardiac or pulmonary conditions that limit ambulation or results in dyspnea with ambulation with walking required as part of activities of daily living.
  • Reported allergy to blueberry or ingredients in the placebo.
  • Ethanol use estimated to be on average > 2 servings/day of beer (12-ounces), wine (5 ounces) or liquor (1.5 ounces), or self-reported binge-drinking.
  • Illicit drug use in the last 12 months.
  • Cigarette smoking within the last 6 months or current use of nicotine.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: blueberry
Participants randomized into this arm of the study consume freeze-dried blueberry.
12g freeze-dried blueberry (powder), twice daily with water, for 90 days
Placebo Comparator: placebo
Participants randomized into this arm of the study consume a blueberry placebo.
12g blue, blueberry-flavored powder, twice daily with water, for 90 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cognition
Time Frame: change from baseline at 45 days
Spatial memory and learning (Morris water maze); short-term memory (digit span), verbal learning and memory (California verbal learning Test), executive function (trail making test, task switching test), attention (attention network test)
change from baseline at 45 days
cognition
Time Frame: Change from baseline at 90 days
Spatial memory and learning (Morris water maze); short-term memory (digit span), verbal learning and memory (California verbal learning Test), executive function (trail making test, task switching test), attention (attention network test)
Change from baseline at 90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gait
Time Frame: Change from baseline at 90 days
gait speed, step length variability, step width variability via instrumented treadmill
Change from baseline at 90 days
Gait
Time Frame: Change from baseline at 45 days
gait speed, step length variability, step width variability via instrumented treadmill
Change from baseline at 45 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Balance
Time Frame: Change from baseline at 45 days
sway velocity and sway area via pressure-sensor
Change from baseline at 45 days
Balance
Time Frame: Change from baseline at 90 days
sway velocity and sway area via pressure-sensor
Change from baseline at 90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Edward Saltzman, MD, Tufts University
  • Study Director: Barbara Shukitt-Hale, PhD, USDA/ARS

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Actual)

February 1, 2014

Study Completion (Actual)

February 1, 2014

Study Registration Dates

First Submitted

June 13, 2013

First Submitted That Met QC Criteria

June 25, 2013

First Posted (Estimate)

June 28, 2013

Study Record Updates

Last Update Posted (Estimate)

May 27, 2015

Last Update Submitted That Met QC Criteria

May 26, 2015

Last Verified

May 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • USDAHNRC-2013-1
  • 1950-51000-070-19R (Other Grant/Funding Number: USHBC)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aging

Clinical Trials on Freeze-dried Blueberry

3
Subscribe